"I am very pleased that the unique technological building blocks we have developed for our products, can now be used for the treatment of debilitating diseases otherwise refractory to other treatments, within SORIN GROUP," said Mr. Michel Troosters, founder and past CEO.
"This acquisition represents a further important step forward in our long-term growth initiatives as announced in our recent Strategic Plan," said André-
, Chief Executive Officer of Sorin Group.
, Rector of UCL, added: "Building bridges between science and industry for the benefits of society is one of the key missions of UCL. Our research, through an integrated technology transfer process, contributes directly to address unmet therapeutic needs."
Founded in 1994 as a spin-off of Université catholique de Louvain, NeuroTECH's mission (
) is to design, develop and bring to market cost-effective active implantable medical devices improving the quality of life of patients suffering from neurological, psychiatric and related disorders. Neurotech's first commercial product, an implantable vagus nerve stimulator, presents two key differentiators: the ADNS-300 uses a rechargeable battery and not only stimulates the vagus nerve but also records neural activity from the left vagus nerve using an innovative cuff electrode. This unique sensing feature enables the physician to capture the "compound action potential" (CAP) generated by the stimulation, which should allow an improved and personalized treatment.
About Sorin Group
Sorin Group (Reuters Code: SORN.MI) is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries. (